Navigation Links
Studies assess genetics, modified treatment to improve outcomes, reduce toxicity
Date:12/8/2012

ATRA+idarubicin (AIDA) treatment regimen. The primary study objective was event-free survival (EFS) at two years, with secondary objectives including overall survival (OS), disease-free survival (DFS), cumulative incidence of relapse (CIR) rates, molecular response, and safety.

Results suggest that the targeted ATO+ATRA therapy strategy might offer similar efficacy to the chemotherapy-based regimen. In the 154 patients who were evaluable for response, complete remission was achieved in all patients (100%) in the ATO+ATRA arm and 95 percent in the AIDA arm. EFS was observed in 97 percent in the ATO+ATRA arm, with one death and two relapses, compared to 86.7 percent in the AIDA arm, in which seven deaths and four relapses were observed. Overall survival, DFS, and CIR rates were 98.7 percent, 97 percent, and 1.6 percent, respectively, in the ATO+ATRA arm, versus 91.1 percent, 91.6 percent, and 4.3 percent, respectively, in the AIDA arm. Additionally, fewer side effects (fever, low neutrophil and platelet counts) were observed in the ATO+ATRA arm.

"This is one of the first times that we can report the success of a treatment strategy for an acute leukemia that relies solely on targeted molecular therapy," said Francesco Lo-Coco, MD, lead author and Chairman of the APL subcommittee of the Italian GIMEMA group and Professor of Hematology at University Tor Vergata in Rome, Italy. "Our results are an important step toward the further utilization of targeted therapies for other types of leukemia, as we begin to focus on improving the overall treatment experience for patients by offering new strategies that deliver the same efficacy as traditional options with considerably lower toxicity."

Dr. Lo-Coco will present this study during the Plenary Scientific Session on Sunday, December 9, at 3:45 p.m. EST at the Georgia World Congress Center in Hall B5, Level 1, Building B.


'/>"/>
Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. John Theurer Cancer Center to present 37 studies at the 2012 ASH Annual Meeting
2. Benefit6 Whole Body Protection, a New Product by I Do Strive LLC, Provides Increased Energy Production According to Recent Studies
3. Sharp spike in computer-related injuries predicted for medical workers, find studies
4. Analysis of conflicting fish oil studies finds that omega-3 fatty acids still matter
5. Studies from 2012 Quality Care Symposium highlight findings in improving quality of cancer care
6. New studies show effects of mammography guideline changes
7. 2 NIH studies show power of epidemiology research; Underscore need to address health disparities
8. Scripps studies show community-based diabetes programs are key to lowered costs and improved care
9. Cancer Drug Reduced Relapses in MS Patients: Studies
10. University of Houston India Studies Program presents Circuits of Empire: India as Metropole
11. Studies Show Limits, Promise of Laser Removal of Tattoos
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... NJ (PRWEB) February 28, 2015 ... a good time to remind ourselves and others ... ignored, say Atlantic NeuroSurgical Specialists (ANS). , Concussions ... which account for 75% of TBIs. There are ... concussion may sound benign, but it is a ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 A study ... promising new gene therapy procedure for the treatment of ... in patients. Authored by Dr. Robert MacLaren, ... published in the Lancet Medical Journal on January 16, ... choroideremia, a rare genetic disorder that mostly affects men ...
(Date:2/28/2015)... St. Louis, MO (PRWEB) February 28, 2015 ... a leading provider of outsourced sales, marketing and ... announces their client, BIOTA Botanicals, is bringing its ... , Celebrated worldwide, BIOTA Botanicals’ products are specifically ... the herbal care experts, BIOTA is committed to ...
(Date:2/28/2015)... 2015 Kaylie Corrigan, Outdoor Supervisor at ... , and current student obtaining her Masters degree in ... weekly forum in psychoeducation on substance use for teens ... as part of her studies. , “Even though these ... and counseling at the high school and junior high ...
(Date:2/28/2015)... February 28, 2015 The noted Toronto ... Facial Surgery was recently featured in the January/February 2015 ... magazine, Dr. David Ellis was featured in an article ... various cosmetic enhancements that Kim Cattrall has possibly undergone ... “Her forehead is smooth without horizontal lines or frown ...
Breaking Medicine News(10 mins):Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:Dr. David Ellis Featured In Elevate Magazine 2
... GAITHERSBURG, Maryland, July 2 ,ExonHit Therapeutics (ALTERNEXT-NYSE ... drug and diagnostic company, today announced its ... (ICAD 2008) taking,place in Chicago (Illinois), July ... ExonHit will reveal several posters and participate,in ...
... Wellcome Trust Sanger Institute has sequenced the equivalent of 300 ... just reached the staggering total of 1,000,000,000,000 letters of genetic ... to understand the role of genes in health and disease. ... few years ago and human medical genetics will be transformed. ...
... WILMINGTON, Del., July 1 AstraZeneca (NYSE:,AZN) today ... District of New,Jersey has granted the company,s Motion ... sued Teva Pharmaceutical Industries,Ltd. and Sandoz, Inc. alleging ... and Sandoz,s filings of Abbreviated New Drug Applications,(ANDAs). ...
... Accomplishes Specific Goals of All Parties -, MONETT, ... JKHY ), a leading provider of integrated technology ... its insurance agency outsourcing solution has been bought by ... Terms of the,transaction were not disclosed., Banc Insurance ...
... 1, 2008) -- Women may respond less favorably ... enlarged heart, according to NewYork-Presbyterian Hospital/Weill Cornell Medical ... have uncovered that women derive a lesser benefit ... losartan and atenolol -- for the reduction of ...
... Increase Over Prior Year and Sixth ... Year Over Year Revenue Growth, SAN DIEGO, July ... BioZ(R) Impedance Cardiography (ICG),technology, today reported financial results for ... first half fiscal 2008,15% quarterly revenue increase over prior ...
Cached Medicine News:Health News:ExonHit Presents Therapeutic and Diagnostic Programs for Alzheimer's at ICAD 2008 2Health News:ExonHit Presents Therapeutic and Diagnostic Programs for Alzheimer's at ICAD 2008 3Health News:ExonHit Presents Therapeutic and Diagnostic Programs for Alzheimer's at ICAD 2008 4Health News:15 human genomes each week 2Health News:15 human genomes each week 3Health News:Summary Judgment Granted for SEROQUEL(R) Patent Litigation 2Health News:Summary Judgment Granted for SEROQUEL(R) Patent Litigation 3Health News:Summary Judgment Granted for SEROQUEL(R) Patent Litigation 4Health News:Summary Judgment Granted for SEROQUEL(R) Patent Litigation 5Health News:Jack Henry & Associates Divests Insurance Agency Outsourcing Business Line 2Health News:Jack Henry & Associates Divests Insurance Agency Outsourcing Business Line 3Health News:Gender differences and heart disease 2Health News:CardioDynamics Reports Second Fiscal Quarter 2008 Results, 18% Revenue Increase for First Half 2008 2Health News:CardioDynamics Reports Second Fiscal Quarter 2008 Results, 18% Revenue Increase for First Half 2008 3Health News:CardioDynamics Reports Second Fiscal Quarter 2008 Results, 18% Revenue Increase for First Half 2008 4Health News:CardioDynamics Reports Second Fiscal Quarter 2008 Results, 18% Revenue Increase for First Half 2008 5Health News:CardioDynamics Reports Second Fiscal Quarter 2008 Results, 18% Revenue Increase for First Half 2008 6
(Date:2/27/2015)... 2015  Uroplasty, Inc. (NASDAQ: UPI ), a ... proprietary products to treat voiding dysfunctions, today announced that ... on Tuesday, March 10, 2015. Rob Kill , ... Financial Officer, will present at 4:00 p.m. Pacific Time ... conference at the Ritz Carlton in Laguna ...
(Date:2/26/2015)... 2015 RnRMarketResearch.com adds Corneal ... report to its store. This report p provides ... The report "Corneal Ulcers - Pipeline Review, H2 ... for Corneal Ulcers. Corneal Ulcers are primarily result ... viral infections & fungal infections. The symptoms of ...
(Date:2/26/2015)... , Feb. 26, 2015  Mobility Ventures LLC, ... agreement with Bank of America (NYSE: BAC ... to receive financing of the revolutionary MV-1 - - ... from the ground up to provide safe and comfortable ... can use their loan to purchase a new MV-1 ...
Breaking Medicine Technology:Uroplasty to Participate in the 27th Annual ROTH Conference 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3
... 2011 Inovio Pharmaceuticals, Inc. (NYSE Amex: ... and preventive vaccines against cancers and infectious diseases, announced ... partnering and scientific conferences: BioPartnering North ... corporate overview on Inovio at the 9th Annual BioPartnering ...
... Feb. 21, 2011 Acuo Technologies®, a market ... medical imaging industry for archiving, collaboration and migration ... Fiscal Year 2010. The company achieved 25% growth ... three-year compounded annual growth rate of 55% in ...
Cached Medicine Technology:Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences 2Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences 3Acuo Technologies Announces Another Significant Growth Year in Revenue and Implementations to Further the Company's Market Leading Position 2
ThyroTest TSH is a rapid, qualitative test for hypothyroidism screening in adults....
... is an ultra-high speed, high resolution optical ... retina imaging and analysis. It ... Optical Coherence technology just emerging from clinical ... The ultra-high speed and high resolution ...
... finest surgical-quality loupes available at ... for innovative optical design, combining superior ... optimum performance with maximum comfort, SheerVision ... medical professionals worldwide. All SheerVision loupes ...
... the finest surgical-quality loupes available ... standard for innovative optical design, combining ... Delivering optimum performance with maximum comfort, ... for medical professionals worldwide. All SheerVision ...
Medicine Products: